Designer Phages Market: Growth Trends and Regional Insights

The global Designer Phages Market was valued at USD 2.49 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.0% from 2025 to 2030. This growth is primarily driven by the rising healthcare expenditure across major economies, which has led to increased investments in advanced therapeutic solutions and biotechnology research. Designer phages, engineered to target specific bacterial strains, are gaining traction as promising alternatives to antibiotics, addressing the growing global concern over antimicrobial resistance.

Download Free Sample

North America currently holds the largest share of the designer phages market and is expected to maintain its dominance throughout the forecast period. The region’s leadership is supported by substantial healthcare spending , strong research and development infrastructure, and a growing focus on precision medicine. These factors collectively enhance innovation in phage therapy and accelerate the clinical adoption of designer phages in various therapeutic applications.

Key companies contributing to the advancement of this market include BiomX Ltd., Micreos, Phaxiam, Locus Biosciences, Inc., and Proteon Pharmaceuticals. These industry players are actively engaged in developing targeted bacteriophage-based therapies, forming strategic collaborations, and investing in R&D to expand their product portfolios and strengthen their global presence.